SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001072613-20-000096
Filing Date
2020-02-13
Accepted
2020-02-13 16:50:22
Documents
1
Group Members
ARCH VENTURE PARTNERS VII, L.P.ARCH VENTURE PARTNERS VII, LLCCLINTON BYBEEKEITH CRANDELLROBERT NELSEN

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND VII, L.P. - SYROS PHARMACEUTICALS, INC. -- SCHEDULE 13G/A(#3) archvii-syros_13ga318372.htm SC 13G/A 232481
  Complete submission text file 0001072613-20-000096.txt   234309
Mailing Address 8755 W HIGGINS SUITE 1025 Chicago IL 60631
Business Address 8755 W HIGGINS SUITE 1025 Chicago IL 60631 773-380-6600
ARCH Venture Fund VII, L.P. (Filed by) CIK: 0001402439 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: SC 13G/A

Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Subject) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89552 | Film No.: 20611553
SIC: 2834 Pharmaceutical Preparations